SeaSpine (SPNE) 10-Q 3 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	Apr. 30, 2018
Document Documentand Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Trading Symbol	SPNE
Entity Registrant Name	SeaSpine Holdings Corporation
Entity Central Index Key	1,637,761
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		14,536,314

CONDENSED COMBINED STATEMENT OF

CONDENSED COMBINED STATEMENT OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Total revenue, net	$ 33,175	$ 31,894
Cost of goods sold	12,179	13,172
Gross profit	20,996	18,722
Selling, general and administrative	24,467	23,970
Research and development	2,789	3,050
Intangible amortization	792	792
Total operating expenses	28,048	27,812
Operating loss	(7,052)	(9,090)
Other income (expense), net	20	(13)
Loss before income taxes	(7,032)	(9,103)
Provision for income taxes	73	0
Net loss	$ (7,105)	$ (9,103)
Net loss per share, basic and diluted	$ (0.50)	$ (0.79)
Weighted average shares used to compute basic and diluted net loss per share	14,085	11,586

CONDENSED COMBINED STATEMENTS O

CONDENSED COMBINED STATEMENTS OF COMPREHENSIVE LOSS Statement - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Statement of Comprehensive Income [Abstract]
Net loss	$ (7,105)	$ (9,103)
Foreign currency translation adjustments	240	81
Comprehensive loss	$ (6,865)	$ (9,022)

CONDENSED COMBINED BALANCE SHEE

CONDENSED COMBINED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 12,470	$ 10,788
Trade accounts receivable, net of allowances of $492 and $466	20,639	21,872
Inventories	43,285	41,721
Prepaid expenses and other current assets	1,779	2,037
Total current assets	78,173	76,418
Property, plant and equipment, net	21,674	22,063
Intangible assets, net	33,583	35,207
Other assets	720	786
Total assets	134,150	134,474
Current liabilities:
Accounts payable, trade	7,700	7,385
Accrued compensation	4,145	5,833
Accrued commissions	4,514	5,793
Contingent consideration liabilities	897	207
Other accrued expenses and current liabilities	4,189	3,939
Total current liabilities	21,445	23,157
Contingent consideration liabilities	3,573	4,228
Other liabilities	1,507	1,436
Total liabilities	26,525	28,821
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value; 15,000 authorized; no shares issued and outstanding at March 31, 2018 and December 31, 2017	0	0
Common stock, $0.01 par value; 60,000 authorized; 14,535 and 13,508 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	146	135
Additional paid-in capital	215,670	206,844
Accumulated other comprehensive income	2,190	1,950
Accumulated deficit	(110,381)	(103,276)
Total stockholders' equity	107,625	105,653
Total liabilities and stockholders' equity	$ 134,150	$ 134,474

CONDENSED COMBINED BALANCE SHE5

CONDENSED COMBINED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Allowance for trade accounts receivable	$ 492	$ 466
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	15,000,000	15,000,000
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	60,000,000	60,000,000
Common Stock, Shares, Issued	14,535,000	13,508,000
Common Stock, Shares, Outstanding	14,535,000	13,508,000

CONDENSED COMBINED STATEMENTS 6

CONDENSED COMBINED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
OPERATING ACTIVITIES:
Net loss	$ (7,105)	$ (9,103)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,643	2,715
Instrument replacement expense	345	494
Provision for excess and obsolete inventories	663	1,091
Amortization of debt issuance costs	35	35
Deferred income tax provision	44	18
Stock-based compensation	835	1,226
Loss from change in fair value of contingent consideration liabilities	74	185
Changes in assets and liabilities:
Accounts receivable	1,255	1,623
Inventories	(1,928)	1,651
Prepaid expenses and other current assets	260	(491)
Other non-current assets	0	(20)
Accounts payable	754	(870)
Accrued commissions	(1,278)	435
Other accrued expenses and current liabilities	(1,417)	599
Other non-current liabilities	174	60
Net cash used in operating activities	(4,646)	(352)
INVESTING ACTIVITIES:
Purchases of property and equipment	(1,691)	(902)
Additions to technology assets	0	(200)
Net cash used in investing activities	(1,691)	(1,102)
FINANCING ACTIVITIES:
Repayments of short-term debt		(378)
Proceeds from issuance of common stock, net of offering costs- ATM transactions	8,514	0
Repurchases of common stock for income tax withheld upon vesting of restricted stock awards	(512)	(45)
Payment for Contingent Consideration Liability, Financing Activities	(39)	0
Net cash provided by (used in) financing activities	7,963	(423)
Effect of exchange rate changes on cash and cash equivalents	56	37
Net change in cash and cash equivalents	1,682	(1,840)
Cash and cash equivalents at beginning of period	10,788	14,566
Cash and cash equivalents at end of period	12,470	12,726
Non-cash investing activities:
Property and equipment in liabilities	459	1,032
Settlement of contingent closing consideration liabilities in connection with acquisition of business	$ 0	$ 2,548

CONDENSED COMBINED STATEMENT O7

CONDENSED COMBINED STATEMENT OF EQUITY Statement - 3 months ended Mar. 31, 2018 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]
Beginning Balance, Shares, Outstanding at December 31, 2017 at Dec. 31, 2017	13,508,000	13,508,000
Beginning Balance at December 31, 2017 at Dec. 31, 2017	$ 105,653	$ 135	$ 206,844	$ 1,950	$ (103,276)
Net loss	(7,105)				(7,105)
Foreign currency translation adjustment	240			240
Issuance of common stock upon vesting of restricted stock units		147,000
Issuance of common stock upon vesting of restricted stock units	0	$ 2	(2)
Issuance of common stock, net of offering costs- ATM transactions		882,000
Issuance of common stock, net of offering costs- ATM transactions	8,514	$ 9	8,505
Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units		(2,000)
Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units	(512)		(512)
Stock-based compensation	$ 835		835
Ending Balance, Shares, Outstanding March 31, 2018 at Mar. 31, 2018	14,535,000	14,535,000
Ending Balance at March 31, 2017 at Mar. 31, 2018	$ 107,625	$ 146	$ 215,670	$ 2,190	$ (110,381)

BUSINESS

BUSINESS	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS	BUSINESS AND BASIS OF PRESENTATION Business SeaSpine Holdings Corporation was incorporated in Delaware on February 12, 2015 in connection with the spin-off of the orthobiologics and spinal implant business of Integra LifeSciences Holdings Corporation, a diversified medical technology company. The spin-off occurred on July 1, 2015. Unless the context indicates otherwise, (i) references to "SeaSpine" or the "Company" refer to SeaSpine Holdings Corporation and its wholly-owned subsidiaries, and (ii) references to "Integra" refer to Integra LifeSciences Holdings Corporation and its subsidiaries other than SeaSpine. Basis of Presentation and Principles of Consolidation The Company prepared the unaudited interim condensed consolidated financial statements included in this report in accordance with accounting principles generally accepted in the U.S. (GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission (SEC) related to quarterly reports on Form 10-Q. The Company’s financial statements are presented on a consolidated basis. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The unaudited interim condensed consolidated financial statements do not include all information and disclosures required by GAAP for annual audited financial statements and should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K filed with the SEC. In the opinion of management, the unaudited interim condensed consolidated financial statements included in this report have been prepared on the same basis as the Company's audited consolidated financial statements and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations, cash flows, and statement of equity for periods presented. The results for the three months ended March 31, 2018 are not necessarily indicative of the results expected for the full year. The condensed consolidated balance sheet as of December 31, 2017 was derived from the audited consolidated financial statements for the year ended December 31, 2017.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and other credits, net realizable value of inventories, discount rates and estimated projected cash flows used to value and test impairments of identifiable intangible and long-lived assets, assumptions related to the timing and probability of product launch dates, discount rates matched to the estimated timing of payments, probability of success rates and discount adjustments on the related cash flows for contingent considerations in business combinations, depreciation and amortization periods for identifiable intangible and long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. Recent Accounting Standards Not Yet Adopted The Company qualifies as an “emerging growth company” (EGC) pursuant to the provisions of the Jumpstart Our Business Startups (JOBS) Act and elected to take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, which permits EGCs to defer compliance with new or revised accounting standards (the EGC extension) until non-issuers are required to comply with such standards. Accordingly, so long as the Company continues to qualify as an EGC, the Company will not have to adopt or comply with new or revised accounting standards until non-issuers are required to adopt or comply with such standards. In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU or Update) No. 2014-09, Revenue from Contracts with Customers (Topic 606) . The new standard provides a five-step approach to be applied to all contracts with customers. The new standard also requires expanded disclosure about revenue recognition. The new standard as amended by ASU 2015-14, ASU 2016-10 and ASU 2016-12, will be effective for the Company beginning on January 1, 2019. The Company performed a preliminary assessment of the impact of this new standard on its consolidated financial statements. In assessing the impact, the Company has outlined all revenue streams, and has considered the five steps outlined in the standard for product sales, from which substantially all the Company's revenue is generated. The Company plans to adopt the new standard using the modified retrospective method. The Company will continue to evaluate the future impact of the new standard throughout 2018. In February 2016, the FASB issued Update No. 2016-02, Leases (Topic 842) . The new standard requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new standard must be adopted using the modified retrospective approach. The standard will be effective for the Company beginning on January 1, 2020 with early adoption permitted. The Company does not plan to early adopt and expects to apply the transition practical expedients allowed by the standard. Note 10 to the Condensed Consolidated Financial Statements provides details on the Company’s current lease arrangements. While the Company continues to evaluate the impact of this new standard on its consolidated financial statements, the Company currently expects the primary impact will be to record right-of-use assets and lease liabilities for existing operating leases in the consolidated balance sheets. The Company does not currently expect the adoption of this new standard to have a material impact on its consolidated results of operations or cash flows. In August 2016, the FASB issued Update No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard addresses eight specific cash flow issues related to cash receipts and cash payments with the objective of reducing the existing diversity of presentation and classification in the statement of cash flows. The new standard will be effective for the Company beginning on January 1, 2019. Early adoption is permitted and should be applied using a retrospective transition method to each period presented. The Company is in the process of evaluating the impact of this standard on its consolidated financial statements. Recently Adopted Accounting Standards In May 2017, the FASB issued Update No. 2017-09, Compensation- Stock Compensation (Topic 718): Scope of Modification Accounting. The new standard provides guidance regarding which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard was effective for the Company beginning on January 1, 2018. Adoption of this new guidance had no impact on the Company’s consolidated financial statements. Net Loss Per Share Basic and diluted net loss per share was calculated using the weighted-average number of shares of common stock outstanding during the period. The weighted average number of shares used to compute diluted net loss per share excludes any assumed exercise of stock options, any assumed issuance of common stock under restricted stock awards and units, and any assumed issuances under the Company's 2015 Employee Stock Purchase Plan, as the effect, in each case, would be antidilutive. Common stock equivalents of 3.6 million and 3.3 million shares for the three months ended March 31, 2018 , and 2017 , respectively, were excluded from the calculation because of their antidilutive effect.

TRANSACTIONS WITH INTEGRA

TRANSACTIONS WITH INTEGRA	3 Months Ended
	Mar. 31, 2018
Related Party Transactions [Abstract]
TRANSACTIONS WITH INTEGRA	TRANSACTIONS WITH INTEGRA Prior to the spin-off, and pursuant to certain supply agreements subsequent to the spin-off, SeaSpine purchased a portion of raw materials and finished goods from Integra for SeaSpine's Mozaik family of products, and SeaSpine contract manufactured certain finished goods for Integra. The Company's purchases of raw materials and Mozaik product finished goods from Integra totaled $0.3 million for the three months ended March 31, 2018 , and there were no such purchases for the same period in 2017 . The Company's sale of finished goods to Integra under its contract manufacturing arrangement for the three months ended March 31, 2018 and 2017 totaled $0.1 million and $0.2 million , respectively.

DEBT AND INTEREST

DEBT AND INTEREST	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	DEBT AND INTEREST Credit Agreement In December 2015, the Company entered into a three -year credit facility with Wells Fargo Bank, National Association, which was subsequently amended in October 2016 (as amended, the Credit Facility). The Credit Facility provides an asset-backed revolving line of credit of up to $30.0 million in borrowing capacity with a maturity date of December 24, 2018, which maturity date is subject to a one-time, one -year extension at the Company's election. In connection with the Credit Facility, the Company was required to become a guarantor and to provide a security interest in substantially all its assets for the benefit of the counterparty. Borrowings under the Credit Facility accrue interest at the rate then applicable to base rate loans (as customarily defined), unless and until converted into LIBOR rate loans (as customarily defined) in accordance with the terms of the Credit Facility. Borrowings bear interest at a floating annual rate equal to (a) during any month for which the Company's average excess availability (as customarily defined) is greater than $20.0 million , (i) base rate plus 1.25 percentage points for base rate loans and (ii) LIBOR rate plus 2.25 percentage points for LIBOR rate loans, (b) during any month for which the Company's average excess availability is greater than $10.0 million but less than or equal to $20.0 million , (i) base rate plus 1.50 percentage points for base rate loans and (ii) LIBOR rate plus 2.50 percentage points for LIBOR rate loans and (c) during any month for which the Company's average excess availability is less than or equal to $10.0 million , (i) base rate plus 1.75 percentage points for base rate loans and (ii) LIBOR rate plus 2.75 percentage points for LIBOR rate loans. The Company will also pay an unused line fee in an amount equal to 0.375% per annum of the amount unused under the Credit Facility. The unused line fee is due and payable on the first day of each month. During 2017, the Company paid off the entire amount borrowed under the Credit Facility plus accrued interest, totaling $4.1 million . There were no amounts outstanding under the Credit Facility at March 31, 2018 and December 31, 2017 . At March 31, 2018 , the Company had $19.7 million of current borrowing capacity under the Credit Facility. Debt issuance costs and legal fees related to the Credit Facility totaling $0.4 million were recorded as a deferred asset and are being amortized ratably over the term of the arrangement. The Credit Facility contains various customary affirmative and negative covenants, including prohibiting the Company from incurring indebtedness without the lender’s consent. The Credit Facility also includes a financial covenant that requires the Company to maintain a minimum fixed charge coverage ratio of 1.10 to 1.00 for the applicable measurement period, if the Company's Total Liquidity (as defined in the Credit Facility) is less than $5.0 million . The Company was in compliance with all applicable covenants at March 31, 2018 . The Credit Facility also includes customary events of default, including events of default relating to non-payment of amounts due under the Credit Facility, material inaccuracy of representations and warranties, violation of covenants, bankruptcy and insolvency, failure to comply with health care laws, violation of certain of the Company’s existing agreements, and the occurrence of a change of control. Under the Credit Facility, if an event of default occurs, the lender will have the right to terminate the commitments and accelerate the maturity of any loans outstanding.

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2018
Inventory, Net [Abstract]
INVENTORIES	INVENTORIES Inventories consisted of the following: March 31, 2018 December 31, 2017 (In thousands) Finished goods $ 30,601 $ 31,008 Work in process 7,759 6,909 Raw materials 4,925 3,804 $ 43,285 $ 41,721

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	3 Months Ended
	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment are stated at historical cost less accumulated depreciation and any impairment charges. The Company provides for depreciation using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the lease term or the useful life. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred. The cost of computer software obtained for internal use is accounted for in accordance with the Accounting Standards Codification (ASC) 350-40, Internal-Use Software. The cost of purchased spinal instruments which the Company consigns to hospitals and independent sales agents to support surgeries is initially capitalized as construction in progress. The amount is either then reclassified to spinal instruments and sets and depreciation is initiated when instruments are put together in a newly built set with spinal implants, or directly expensed for the instruments that are used to replace damaged instruments in an existing set. The depreciation expense and direct expense for replacement instruments are recorded in selling, general and administrative expense. Property, plant and equipment balances and corresponding useful lives were as follows: March 31, 2018 December 31, 2017 Useful Lives (In thousands) Leasehold improvement $ 5,510 $ 5,312 Lease Term Machinery and production equipment 7,154 7,030 3-10 years Spinal instruments and sets 21,136 20,340 5 years Information systems and hardware 7,428 7,375 3-7 years Furniture and fixtures 1,001 991 3-5 years Construction in progress 7,474 8,136 Total 49,703 49,184 Less accumulated depreciation and amortization (28,029 ) (27,121 ) Property, plant and equipment, net $ 21,674 $ 22,063 Depreciation expenses totaled $1.0 million and $1.0 million for the three months ended March 31, 2018 and 2017 , respectively. The cost of purchased instruments used to replace damaged instruments in existing sets and recorded directly to the instrument replacement expense totaled $0.3 million and $0.5 million for the three months ended March 31, 2018 and 2017 , respectively.

IDENTIFIABLE INTANGIBLE ASSETS

IDENTIFIABLE INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
IDENTIFIABLE INTANGIBLE ASSETS	IDENTIFIABLE INTANGIBLE ASSETS Identifiable intangible assets are initially recorded at fair value at the time of acquisition, generally using an income or cost approach. The Company capitalizes costs incurred to renew or extend the term of recognized intangible assets and amortizes those costs over their expected useful lives. The components of the Company’s identifiable intangible assets were as follows: March 31, 2018 Weighted Average Life Cost Accumulated Amortization Net (Dollars in thousands) Product technology 12 years $ 40,769 $ (26,658 ) $ 14,111 Customer relationships 12 years 56,830 (37,358 ) 19,472 Trademarks/brand names — 300 (300 ) — $ 97,899 $ (64,316 ) $ 33,583 December 31, 2017 Weighted Average Life Cost Accumulated Amortization Net (Dollars in thousands) Product technology 12 years $ 40,769 $ (25,827 ) $ 14,942 Customer relationships 12 years 56,830 (36,565 ) 20,265 Trademarks/brand names — 300 (300 ) — $ 97,899 $ (62,692 ) $ 35,207 Annual amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $6.5 million in 2018 , $5.8 million in 2019 , $4.9 million in 2020 , $4.9 million in 2021 and $4.8 million in 2022 . Amortization expense totaled $1.6 million and $1.7 million for the three months ended March 31, 2018 and 2017 , respectively, and included $0.8 million and $0.9 million , respectively, of amortization of product technology intangible assets that is presented within cost of goods sold.

FAIR VALUE MEASUREMENTS (Notes)

FAIR VALUE MEASUREMENTS (Notes)	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	FAIR VALUE MEASUREMENTS The Company is obligated to pay up to a maximum of $5.0 million in milestone payments in connection with the August 2016 asset purchase transaction with N.L.T Spine Ltd. (NLT) and NLT Spine, Inc., a wholly owned subsidiary of NLT, payable at the Company's election in cash or in shares of its common stock. Such milestone payments are contingent on the Company's achievement of four independent events related to the commercialization of the product technologies the Company acquired in the transaction. Additionally, the Company is required to pay royalty payments, in cash, to NLT equal to declining (over time) percentages of the Company’s future net sales of certain of the acquired product technologies not to exceed $43.0 million in the aggregate. The Company has the option to terminate any future obligation to make royalty payments by making a one-time cash payment to NLT of $18.0 million . The fair values of the Company’s assets and liabilities, including contingent consideration liabilities mentioned above, are measured at fair value on a recurring basis, and are determined under the fair value categories as follows (in thousands): Total Quoted Price in Active Market (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) March 31, 2018: Contingent consideration liabilities- current $ 897 $ — $ — $ 897 Contingent consideration liabilities- non-current 3,573 — — 3,573 Total contingent consideration $ 4,470 $ — $ — $ 4,470 December 31, 2017: Contingent consideration liabilities- current $ 207 $ — $ — $ 207 Contingent consideration liabilities- non-current 4,228 — — 4,228 Total contingent consideration $ 4,435 $ — $ — $ 4,435 Contingent consideration liabilities are classified within Level 3 of the fair value hierarchy because they use significant unobservable inputs. For those liabilities, fair value is determined using a probability-weighted discounted cash flow model and significant inputs which are not observable in the market. The significant inputs include assumptions related to the timing and probability of the product launch dates, discount rates matched to the timing of payments, and probability of success rates. The following table sets forth the changes in the estimated fair value of the Company’s liabilities measured on a recurring basis using significant unobservable inputs (Level 3). The loss from change in fair value of contingent milestone and royalty payments results from updated estimated timing of payments, probability of success rates, the passage of time, updated discount rates matched to the estimated timing of payments, actual net sales of certain products for the three months ended March 31, 2018 , and estimated net sales for future royalty payment periods. Future changes in estimated timing of payments, probability of success rates, or estimated net sales for upcoming royalty payment periods would be expected to have a material impact on the fair value of contingent milestone and royalty payments. Three Months Ended March 31, 2018: (in thousands) Balance as of January 1, 2018 $ 4,435 Contingent consideration liabilities settled (39 ) Loss from change in fair value of contingent considerations recorded in selling, general and administrative expenses 74 Fair value at March 31, 2018 $ 4,470

EQUITY AND STOCK-BASED COMPENSA

EQUITY AND STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	EQUITY AND STOCK-BASED COMPENSATION Common Stock On January 31, 2017, the Company issued 350,000 shares of common stock to NLT as the settlement of contingent closing consideration pursuant to the terms of the asset purchase agreement entered into with NLT in August 2016. The total fair value of such shares was $2.5 million at issuance. In August 2016, the Company entered into an equity distribution agreement (Distribution Agreement) with Piper Jaffray & Co. (Piper Jaffray), pursuant to which the Company may offer and sell shares of its common stock in “at the market” (ATM) offerings (as defined in Rule 415 of the Securities Act of 1933, as amended) having an aggregate offering price up to $25.0 million in gross proceeds from time to time through Piper Jaffray acting as sales agent. The shares offered and sold under the Distribution Agreement are covered by a registration statement on Form S-3 that was declared effective on August 24, 2016. Under the Distribution Agreement, the Company sold 882,332 shares of common stock at an average price per share of $10.00 and received net proceeds of approximately $8.5 million (net of $0.3 million of offering costs) during the three months ended March 31, 2018 . The Company intends to continue using the net proceeds for general corporate purposes, including sales and marketing expenditures aimed at growing its business, research and development expenditures focused on product development, and investments in inventory and spinal instruments and sets. The Company has consumed the $25.0 million in capacity under the Distribution Agreement as of March 31, 2018 . Equity Award Plans As of June 30, 2015, Integra had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock units outstanding under three plans, the 2000 Equity Incentive Plan, the 2001 Equity Incentive Plan, and the 2003 Equity Incentive Plan. In connection with the spin-off, Integra equity awards granted to individuals who became employees of SeaSpine were converted to equity awards denominated in SeaSpine common stock. In general, each post-conversion award is subject to the same terms and conditions as were applicable to the pre-conversion award. Under the 2015 Incentive Award Plan (2015 Plan), the Company can grant its employees, non-employee directors and consultants incentive stock options and non-qualified stock options, restricted stock, performance stock, dividend equivalent rights, stock appreciation rights, stock payment awards and other incentive awards. The Company may issue up to 3,509,500 shares of its common stock in respect of awards granted under the 2015 Plan. On February 1, 2018, the Company's board of directors approved an amendment of the 2015 Plan, pursuant to which the share reserve was increased by 350,000 shares over the then-existing share reserve under the 2015 Plan, and on March 22, 2018, the Company's board of directors approved a further amendment and restatement of the 2015 Plan, pursuant to which (among other things) the share reserve was increased by an additional 2,376,000 shares, in each case subject to stockholder approval (the amended and restated 2015 Plan, incorporating all of these amendments, is referred to as the Restated Plan). The Company is submitting the Restated Plan to its stockholders for approval at its annual meeting of stockholders scheduled to be held on May 30, 2018. If the Company's stockholders do not approve the Restated Plan by February 1, 2019 (in which case the amendments that the Company's board of directors approved on February 1, 2018 and March 22, 2018 would cease to be effective), as of March 31, 2018 , a total of 319,003 shares would remain available for issuance under the 2015 Plan. In 2016, the Company established the 2016 Employment Inducement Incentive Award Plan (the 2016 Plan). The plan is a broad-based incentive plan which allows for the issuance of stock-based awards, including non-qualified stock options, restricted stock awards, performance awards, restricted stock unit awards and stock appreciation rights, to any prospective officer or other employee who has not previously been an employee or director of the Company or an affiliate or who is commencing employment with the Company or an affiliate following a bona-fide period of non-employment by the Company or an affiliate. An aggregate of 1,000,000 shares are reserved for issuance under the 2016 Plan. If the Restated Plan is approved by the Company's stockholders, the Company's board of directors will not grant any awards under the 2016 Plan. As a result, the only shares the Company would have available for issuance of equity awards (other than pursuant to the Company's employee stock purchase plan) would be the shares reserved for issuance under the Restated Plan. The Company has not awarded any shares under the 2016 Plan as of March 31, 2018 . Assumptions Stock-based compensation expense related to all equity awards includes an estimate for forfeitures. The expected forfeiture rate of all equity-based compensation is based on historical experience of pre-vesting forfeitures on awards and options by each homogenous group of shareowners. For awards and options granted to non-executive employees, the forfeiture rate is estimated to be 15% annually for the three months ended March 31, 2018 and 12% annually for the three months ended March 31, 2017 . There is no forfeiture rate applied to awards or options granted to non-employee directors or executive employees because their pre-vesting forfeitures are anticipated to be highly unlikely. As individual awards and options become fully vested, stock-based compensation expense is adjusted to recognize actual forfeitures. Restricted Stock Awards and Restricted Stock Units The Company expenses the fair value of restricted stock awards and of restricted stock units on an accelerated basis over the vesting period or requisite service period, whichever is shorter. There were zero and 3,982 shares of restricted stock awards granted to non-employee directors during the three months ended March 31, 2018 and 2017 , respectively. There were 465,381 and 730,802 shares of restricted stock units granted to employees during the three months ended March 31, 2018 and 2017 , respectively. Of the total restricted stock units granted to employees in 2018, 341,808 were granted, in part, out of the share reserve increase incorporated by the amendment to the 2015 Plan the Company's board of directors adopted on February 1, 2018, and all of which were granted subject to stockholder approval of the Restated Plan (the Contingent RSUs). If the Company's stockholders do not approve the Restated Plan, all the Contingent RSUs will automatically be forfeited. In accordance with the ASC 718, Compensation-Stock Compensation, there were no expenses recorded for the Contingent RSUs for the three months ended March 31, 2018. Of the total restricted stock units granted to employees in 2017, 131,523 shares were granted in lieu of cash bonuses earned under the annual incentive program for corporate and individual performance in 2016. As of March 31, 2018 , there was approximately $5.2 million of total unrecognized compensation expense related to the unvested portions of restricted stock awards and of restricted stock units. This cost is expected to be recognized over a weighted-average period of approximately 1.9 years . Stock Options Stock option grants to employees generally have a requisite service period of four years, and stock option grants to non-employee directors generally have a requisite service period of one year. Both are subject to graded vesting. The Company records stock-based compensation expense associated with stock options on an accelerated basis over the various vesting periods within each grant and based on their fair value at the date of grant using the Black-Scholes-Merton option pricing model. There were zero and 21,500 stock options granted during the three months ended March 31, 2018 and 2017 , respectively. The following weighted-average assumptions were used in the calculation of fair value for options grants for the period indicated. Three Months Ended March 31, 2017 Expected dividend yield 0 % Risk-free interest rate 2.0 % Expected volatility 35.7 % Expected term (in years) 5.1 The Company considered that it has never paid, and does not currently intend to pay, cash dividends. The risk-free interest rates are derived from the U.S. Treasury yield curve in effect on the date of grant for instruments with a remaining term similar to the expected term of the options. Due to the Company’s limited historical data, the expected volatility is calculated based upon the historical volatility of comparable companies in the medical device industry whose share prices are publicly available for a sufficient period of time. The expected term of "plain vanilla" options is calculated using the simplified method as prescribed by accounting guidance for stock-based compensation. A "plain vanilla" option is an option with the following characteristics: (1) the option is granted at-the-money; (2) exercisability is conditional only on satisfaction of a service condition through the vesting date; (3) employees who terminate their service prior to vesting forfeit the option; (4) employees who terminate their service after vesting are granted limited time to exercise their options; and (5) the option is nontransferable and non-hedgeable. The expected term of any other option is based on disclosures from similar companies with similar grants. In addition, the Company applies an expected forfeiture rate when amortizing stock-based compensation expense. As of March 31, 2018 , there was approximately $0.7 million of total unrecognized compensation expense related to unvested stock options. This cost is expected to be recognized over a weighted-average period of approximately 0.9 years. Employee Stock Purchase Plan In May 2015, the Company adopted the SeaSpine Holdings Corporation 2015 Employee Stock Purchase Plan, which was amended in December 2015 (as amended, the ESPP). Under the ESPP, eligible employees may purchase shares of the Company’s common stock through payroll deductions of up to 15% of eligible compensation during an offering period. Generally, each offering will be for a period of twenty-four months as determined by the Company's board of directors. There are four six-month purchase periods in each offering period for contributions to be made and to be converted into shares at the end of the purchase period. In no event may an employee purchase more than 2,500 shares per purchase period based on the closing price on the first trading date of an offering period or more than $25,000 worth of stock during any calendar year. The purchase price for shares to be purchased under the ESPP is 85% of the lesser of the market price of the Company's common stock on the first trading date of an offering period or on any purchase date during an offering period (June 30 or December 31). The ESPP authorizes the issuance of up to 400,000 shares of common stock pursuant to purchase rights granted to employees. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code of 1986, as amended (the IRC). The ESPP contains a restart feature, such that if the market price of the stock at the end of any six-month purchase period is lower than the market price at the original grant date of an offering period, that offering period will terminate after that purchase date, and a new two-year offering period will commence on the January 1 or July 1 immediately following the date the original offering period terminated. This restart feature was triggered on the purchase date that occurred on December 31, 2016, such that the offering period that commenced on July 1, 2016 was terminated, and a new two-year offering period commenced on January 1, 2017 and is scheduled to end on December 31, 2018. The Company applied share-based payment modification accounting to the awards that were initially valued at the grant date to determine the amount of any incremental fair value associated with the modified awards. The impact to stock-based compensation expense for modifications during the three months ended March 31, 2018 was immaterial. No shares of common stock were purchased under the ESPP during the three months ended March 31, 2018 . The Company recognized $0.1 million in expense related to the ESPP for each of the three months ended March 31, 2018 and 2017 . The Company estimates the fair value of shares issued to employees under the ESPP using the Black-Scholes-Merton option-pricing model. The following weighted average assumptions were used in the calculation of fair value of shares under the ESPP at the grant date for the periods indicated: Three Months Ended March 31, 2018 2017 Expected dividend yield 0 % 0 % Risk-free interest rate 1.8 % 1.0 % Expected volatility 27.7 % 28.5 % Expected term (in years) 1.3 1.3

LEASES

LEASES	3 Months Ended
	Mar. 31, 2018
Leases [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	LEASES The Company leases administrative, manufacturing, research, and distribution facilities and various manufacturing, office and transportation equipment through operating lease agreements. Future minimum lease payments under the Company's operating leases at March 31, 2018 are as follows: Payments Due by Calendar Year (In thousands) 2018 $ 1,549 2019 2,132 2020 2,181 2021 2,223 2022 2,243 Thereafter 6,242 Total minimum lease payments $ 16,570 Total lease expense was $0.5 million and $0.7 million for the three months ended March 31, 2018 and 2017 , respectively.

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The following table provides a summary of the Company’s effective tax rate for the periods indicated: Three Months Ended March 31, 2018 2017 Reported tax rate (1.00 )% — % The Company recorded a provision for income tax expense for the three months ended March 31, 2018 primarily related to foreign and state operations. The Tax Cuts and Jobs Act (the Act) was enacted on December 22, 2017. The Act reduces the U.S. federal corporate rate from 35% to 21%, requires companies to pay a one-time transition tax on accumulated earnings of certain foreign subsidiaries previously deferred from tax and creates a new provision designed to tax global intangible low-taxed income (GILTI). The Company is not subject to the one-time transition tax on accumulated foreign earnings or the GILTI provisions enacted by the Act because the Company's foreign operations have been included in its US tax filings pursuant to an election to disregard its foreign entity for federal income tax purposes. In addition, for all periods presented, the pretax losses incurred by the consolidated U.S. tax group received no corresponding tax benefit because the Company has concluded that it is more likely than not that the Company will be unable to realize the value of any resulting deferred tax assets. The Company will continue to assess its position in future periods to determine if it is appropriate to reduce a portion of its valuation allowance in the future.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products sold by the Company. Except for the royalties payable to NLT, the royalty payments that the Company made under these agreements are included in the consolidated statements of operations as a component of cost of goods sold. The Company is subject to various legal proceedings in the ordinary course of its business with respect to its products, its current or former employees, and its commercial relationships, some of which have been settled by the Company. In the opinion of management, such proceedings are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material adverse effect on the Company's financial condition. However, it is possible that the Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies. The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds, and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. While uncertainty exists, the Company does not believe there are any pending legal proceedings that would have a material impact on the Company’s financial position, cash flows or results of operations.

SEGMENT AND GEOGRAPHIC INFORMAT

SEGMENT AND GEOGRAPHIC INFORMATION	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
SEGMENT AND GEOGRAPHIC INFORMATION	SEGMENT AND GEOGRAPHIC INFORMATION Management assessed its segment reporting based on how it internally manages and reports the results of its business to its chief operating decision maker. Management reviews financial results, manages the business and allocates resources on an aggregate basis. Therefore, financial results are reported in a single operating segment: the development, manufacture and marketing of orthobiologics and of spinal implants. The Company reports revenue in two product categories: orthobiologics and spinal implants. Orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following surgery. The spinal implants portfolio consists of an extensive line of products for minimally invasive surgery, complex spine, deformity and degenerative procedures. Revenue, net consisted of the following: Three Months Ended March 31, 2018 2017 Orthobiologics $ 18,016 $ 17,125 Spinal implants 15,159 14,769 Total revenue, net $ 33,175 $ 31,894 The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following: Three Months Ended March 31, 2018 2017 United States $ 29,538 $ 28,611 International 3,637 3,283 Total revenue, net $ 33,175 $ 31,894

SUMMARY OF SIGNIFICANT ACCOUN21

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and other credits, net realizable value of inventories, discount rates and estimated projected cash flows used to value and test impairments of identifiable intangible and long-lived assets, assumptions related to the timing and probability of product launch dates, discount rates matched to the estimated timing of payments, probability of success rates and discount adjustments on the related cash flows for contingent considerations in business combinations, depreciation and amortization periods for identifiable intangible and long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates.
Recently Issued and Adopted Accounting Standards	Recent Accounting Standards Not Yet Adopted The Company qualifies as an “emerging growth company” (EGC) pursuant to the provisions of the Jumpstart Our Business Startups (JOBS) Act and elected to take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, which permits EGCs to defer compliance with new or revised accounting standards (the EGC extension) until non-issuers are required to comply with such standards. Accordingly, so long as the Company continues to qualify as an EGC, the Company will not have to adopt or comply with new or revised accounting standards until non-issuers are required to adopt or comply with such standards. In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU or Update) No. 2014-09, Revenue from Contracts with Customers (Topic 606) . The new standard provides a five-step approach to be applied to all contracts with customers. The new standard also requires expanded disclosure about revenue recognition. The new standard as amended by ASU 2015-14, ASU 2016-10 and ASU 2016-12, will be effective for the Company beginning on January 1, 2019. The Company performed a preliminary assessment of the impact of this new standard on its consolidated financial statements. In assessing the impact, the Company has outlined all revenue streams, and has considered the five steps outlined in the standard for product sales, from which substantially all the Company's revenue is generated. The Company plans to adopt the new standard using the modified retrospective method. The Company will continue to evaluate the future impact of the new standard throughout 2018. In February 2016, the FASB issued Update No. 2016-02, Leases (Topic 842) . The new standard requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new standard must be adopted using the modified retrospective approach. The standard will be effective for the Company beginning on January 1, 2020 with early adoption permitted. The Company does not plan to early adopt and expects to apply the transition practical expedients allowed by the standard. Note 10 to the Condensed Consolidated Financial Statements provides details on the Company’s current lease arrangements. While the Company continues to evaluate the impact of this new standard on its consolidated financial statements, the Company currently expects the primary impact will be to record right-of-use assets and lease liabilities for existing operating leases in the consolidated balance sheets. The Company does not currently expect the adoption of this new standard to have a material impact on its consolidated results of operations or cash flows. In August 2016, the FASB issued Update No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard addresses eight specific cash flow issues related to cash receipts and cash payments with the objective of reducing the existing diversity of presentation and classification in the statement of cash flows. The new standard will be effective for the Company beginning on January 1, 2019. Early adoption is permitted and should be applied using a retrospective transition method to each period presented. The Company is in the process of evaluating the impact of this standard on its consolidated financial statements. Recently Adopted Accounting Standards In May 2017, the FASB issued Update No. 2017-09, Compensation- Stock Compensation (Topic 718): Scope of Modification Accounting. The new standard provides guidance regarding which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard was effective for the Company beginning on January 1, 2018. Adoption of this new guidance had no impact on the Company’s consolidated financial statements.
Earnings Per Share	Basic and diluted net loss per share was calculated using the weighted-average number of shares of common stock outstanding during the period. The weighted average number of shares used to compute diluted net loss per share excludes any assumed exercise of stock options, any assumed issuance of common stock under restricted stock awards and units, and any assumed issuances under the Company's 2015 Employee Stock Purchase Plan, as the effect, in each case, would be antidilutive. Common stock equivalents of 3.6 million and 3.3 million shares for the three months ended March 31, 2018 , and 2017 , respectively, were excluded from the calculation because of their antidilutive effect.

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2018
Inventory, Net [Abstract]
Schedule of Inventory, Net	Inventories consisted of the following: March 31, 2018 December 31, 2017 (In thousands) Finished goods $ 30,601 $ 31,008 Work in process 7,759 6,909 Raw materials 4,925 3,804 $ 43,285 $ 41,721

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant and equipment balances and corresponding useful lives were as follows: March 31, 2018 December 31, 2017 Useful Lives (In thousands) Leasehold improvement $ 5,510 $ 5,312 Lease Term Machinery and production equipment 7,154 7,030 3-10 years Spinal instruments and sets 21,136 20,340 5 years Information systems and hardware 7,428 7,375 3-7 years Furniture and fixtures 1,001 991 3-5 years Construction in progress 7,474 8,136 Total 49,703 49,184 Less accumulated depreciation and amortization (28,029 ) (27,121 ) Property, plant and equipment, net $ 21,674 $ 22,063

IDENTIFIABLE INTANGIBLE ASSETS

IDENTIFIABLE INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Components of Company's Identifiable Intangible Assets	The components of the Company’s identifiable intangible assets were as follows: March 31, 2018 Weighted Average Life Cost Accumulated Amortization Net (Dollars in thousands) Product technology 12 years $ 40,769 $ (26,658 ) $ 14,111 Customer relationships 12 years 56,830 (37,358 ) 19,472 Trademarks/brand names — 300 (300 ) — $ 97,899 $ (64,316 ) $ 33,583 December 31, 2017 Weighted Average Life Cost Accumulated Amortization Net (Dollars in thousands) Product technology 12 years $ 40,769 $ (25,827 ) $ 14,942 Customer relationships 12 years 56,830 (36,565 ) 20,265 Trademarks/brand names — 300 (300 ) — $ 97,899 $ (62,692 ) $ 35,207

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The fair values of the Company’s assets and liabilities, including contingent consideration liabilities mentioned above, are measured at fair value on a recurring basis, and are determined under the fair value categories as follows (in thousands): Total Quoted Price in Active Market (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) March 31, 2018: Contingent consideration liabilities- current $ 897 $ — $ — $ 897 Contingent consideration liabilities- non-current 3,573 — — 3,573 Total contingent consideration $ 4,470 $ — $ — $ 4,470 December 31, 2017: Contingent consideration liabilities- current $ 207 $ — $ — $ 207 Contingent consideration liabilities- non-current 4,228 — — 4,228 Total contingent consideration $ 4,435 $ — $ — $ 4,435
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth the changes in the estimated fair value of the Company’s liabilities measured on a recurring basis using significant unobservable inputs (Level 3). The loss from change in fair value of contingent milestone and royalty payments results from updated estimated timing of payments, probability of success rates, the passage of time, updated discount rates matched to the estimated timing of payments, actual net sales of certain products for the three months ended March 31, 2018 , and estimated net sales for future royalty payment periods. Future changes in estimated timing of payments, probability of success rates, or estimated net sales for upcoming royalty payment periods would be expected to have a material impact on the fair value of contingent milestone and royalty payments. Three Months Ended March 31, 2018: (in thousands) Balance as of January 1, 2018 $ 4,435 Contingent consideration liabilities settled (39 ) Loss from change in fair value of contingent considerations recorded in selling, general and administrative expenses 74 Fair value at March 31, 2018 $ 4,470

EQUITY AND STOCK-BASED COMPEN26

EQUITY AND STOCK-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Stock option grants to employees generally have a requisite service period of four years, and stock option grants to non-employee directors generally have a requisite service period of one year. Both are subject to graded vesting. The Company records stock-based compensation expense associated with stock options on an accelerated basis over the various vesting periods within each grant and based on their fair value at the date of grant using the Black-Scholes-Merton option pricing model. There were zero and 21,500 stock options granted during the three months ended March 31, 2018 and 2017 , respectively. The following weighted-average assumptions were used in the calculation of fair value for options grants for the period indicated. Three Months Ended March 31, 2017 Expected dividend yield 0 % Risk-free interest rate 2.0 % Expected volatility 35.7 % Expected term (in years) 5.1
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	The Company estimates the fair value of shares issued to employees under the ESPP using the Black-Scholes-Merton option-pricing model. The following weighted average assumptions were used in the calculation of fair value of shares under the ESPP at the grant date for the periods indicated: Three Months Ended March 31, 2018 2017 Expected dividend yield 0 % 0 % Risk-free interest rate 1.8 % 1.0 % Expected volatility 27.7 % 28.5 % Expected term (in years) 1.3 1.3

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2018
Leases [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases	Future minimum lease payments under the Company's operating leases at March 31, 2018 are as follows: Payments Due by Calendar Year (In thousands) 2018 $ 1,549 2019 2,132 2020 2,181 2021 2,223 2022 2,243 Thereafter 6,242 Total minimum lease payments $ 16,570

INCOME TAXES (Tables)

INCOME TAXES (Tables)	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of effective income tax rate reconciliation	The following table provides a summary of the Company’s effective tax rate for the periods indicated: Three Months Ended March 31, 2018 2017 Reported tax rate (1.00 )% — %

SEGMENT AND GEOGRAPHIC INFORM29

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Total Revenue By Major Geographic Area	Revenue, net consisted of the following: Three Months Ended March 31, 2018 2017 Orthobiologics $ 18,016 $ 17,125 Spinal implants 15,159 14,769 Total revenue, net $ 33,175 $ 31,894 The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following: Three Months Ended March 31, 2018 2017 United States $ 29,538 $ 28,611 International 3,637 3,283 Total revenue, net $ 33,175 $ 31,894

SUMMARY OF SIGNIFICANT ACCOUN30

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Narrative (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accounting Policies [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3.6	3.3

TRANSACTIONS WITH INTEGRA Narra

TRANSACTIONS WITH INTEGRA Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Related Party Transaction [Line Items]
Purchases	$ 1,928	$ (1,651)
Integra | Affiliated Entity
Related Party Transaction [Line Items]
Purchases	300
Revenue from Related Parties	$ 100	$ 200

DEBT AND INTEREST Credit Agreem

DEBT AND INTEREST Credit Agreement (Details)	Dec. 24, 2015USD ($)	Mar. 31, 2018USD ($)
Line of Credit Facility [Line Items]
Repayment of Long-Term Debt and Accrued Interest		$ 4,100,000
Document Period End Date		Mar. 31, 2018
Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Expiration Period	3 years
Line Of Credit Facility, Extension Period	1 year
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage		0.375%
Unamortized Debt Issuance Expense	$ 400,000
Debt Instrument, Covenant, Fixed Charge Ratio, Minimum		1.1
Debt Instrument, Covenant Description, Required Liquidity		$ 5,000,000
Credit Agreement [Member] | Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 30,000,000
Line of Credit Facility, Remaining Borrowing Capacity		$ 19,700,000
Credit Agreement, Contingent Interest Rate Three [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate		1.75%
Credit Agreement, Contingent Interest Rate Three [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate		2.75%
Credit Agreement. Contingent Interest Rate Two [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate		1.50%
Credit Agreement. Contingent Interest Rate Two [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate		2.50%
Credit Agreement, Contingent Interest Rate One [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate		1.25%
Credit Agreement, Contingent Interest Rate One [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate		2.25%
Maximum [Member] | Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Current Borrowing Capacity		$ 20,000,000
Minimum [Member] | Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Current Borrowing Capacity		$ 10,000,000

INVENTORIES Schedule of Invento

INVENTORIES Schedule of Inventories, net (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Inventory, Net [Abstract]
Finished goods	$ 30,601	$ 31,008
Work in process	7,759	6,909
Raw materials	4,925	3,804
Inventories, net	$ 43,285	$ 41,721

PROPERTY, PLANT AND EQUIPMENT P

PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment balances (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Depreciation	$ 1,000	$ 1,000
Total	49,703		$ 49,184
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(28,029)		(27,121)
Property, plant and equipment, net	21,674		22,063
Leasehold improvement
Property, Plant and Equipment [Line Items]
Total	$ 5,510		5,312
Leasehold improvement | Minimum
Property, Plant and Equipment [Line Items]
Useful Lives (in years)	1 year
Leasehold improvement | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Lives (in years)	20 years
Machinery and production equipment
Property, Plant and Equipment [Line Items]
Total	$ 7,154		7,030
Machinery and production equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful Lives (in years)	3 years
Machinery and production equipment | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Lives (in years)	10 years
Spinal instruments and sets
Property, Plant and Equipment [Line Items]
Total	$ 21,136		20,340
Spinal instruments and sets | Minimum
Property, Plant and Equipment [Line Items]
Useful Lives (in years)	5 years
Spinal instruments and sets | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Lives (in years)	5 years
Information systems and hardware
Property, Plant and Equipment [Line Items]
Total	$ 7,428		7,375
Information systems and hardware | Minimum
Property, Plant and Equipment [Line Items]
Useful Lives (in years)	3 years
Information systems and hardware | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Lives (in years)	7 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total	$ 1,001		991
Furniture and fixtures | Minimum
Property, Plant and Equipment [Line Items]
Useful Lives (in years)	3 years
Furniture and fixtures | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Lives (in years)	5 years
Construction in progress
Property, Plant and Equipment [Line Items]
Total	$ 7,474		$ 8,136

PROPERTY, PLANT AND EQUIPMENT N

PROPERTY, PLANT AND EQUIPMENT Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation	$ 1,000	$ 1,000
Instrument replacement expense	$ 345	$ 494

IDENTIFIABLE INTANGIBLE ASSET36

IDENTIFIABLE INTANGIBLE ASSETS Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Annual amortization expense expected to approximate in 2018	$ 6.5
Annual amortization expense expected to approximate in 2019	5.8
Annual amortization expense expected to approximate in 2020	4.9
Annual amortization expense expected to approximate in 2021	4.9
Annual amortization expense expected to approximate in 2022	4.8
Intangible asset amortization	1.6	$ 1.7
Product technology | Cost of goods sold
Finite-Lived Intangible Assets [Line Items]
Intangible asset amortization	$ 0.8	$ 0.9

IDENTIFIABLE INTANGIBLE ASSET37

IDENTIFIABLE INTANGIBLE ASSETS Components of Company's Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Cost	$ 97,899		$ 97,899
Accumulated Amortization	(64,316)		(62,692)
Net	$ 33,583		35,207
Product technology
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	12 years	12 years
Cost	$ 40,769		40,769
Accumulated Amortization	(26,658)		(25,827)
Net	$ 14,111		14,942
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	12 years	12 years
Cost	$ 56,830		56,830
Accumulated Amortization	(37,358)		(36,565)
Net	19,472		20,265
Trademarks/brand names
Finite-Lived Intangible Assets [Line Items]
Cost	300		300
Accumulated Amortization	(300)		(300)
Net	$ 0		$ 0

FAIR VALUE MEASUREMENTS Fair Va

FAIR VALUE MEASUREMENTS Fair Value Narrative (Details) $ in Millions	Sep. 26, 2016USD ($)
Milestone Payment [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 5
Royalty payment [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	43
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low	$ 18

FAIR VALUE MEASUREMENTS Fair 39

FAIR VALUE MEASUREMENTS Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Liability, Current, Fair Value Disclosure	$ 897	$ 207
Contingent Consideration Liability, Noncurrent, Fair Value Disclosure	3,573	4,228
Contingent Consideration Liability, Fair Value Disclosure	4,470	4,435
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Liability, Current, Fair Value Disclosure	0	0
Contingent Consideration Liability, Noncurrent, Fair Value Disclosure	0	0
Contingent Consideration Liability, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Liability, Current, Fair Value Disclosure	0	0
Contingent Consideration Liability, Noncurrent, Fair Value Disclosure	0	0
Contingent Consideration Liability, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Liability, Current, Fair Value Disclosure	897	207
Contingent Consideration Liability, Noncurrent, Fair Value Disclosure	3,573	4,228
Contingent Consideration Liability, Fair Value Disclosure	4,470	$ 4,435
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases	$ 39

FAIR VALUE MEASUREMENTS Changes

FAIR VALUE MEASUREMENTS Changes in Contingent Consideration Liabilities (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent Consideration Liability, Current, Fair Value Disclosure	$ 897	$ 207
Fair value of contingent consideration liability, beginning of period	4,435
Fair value of contingent consideration liability, end of period	4,470
Contingent Consideration Liability, Noncurrent, Fair Value Disclosure	3,573	4,228
Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent Consideration Liability, Current, Fair Value Disclosure	0	0
Fair value of contingent consideration liability, beginning of period	0
Fair value of contingent consideration liability, end of period	0
Contingent Consideration Liability, Noncurrent, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent Consideration Liability, Current, Fair Value Disclosure	897	207
Fair value of contingent consideration liability, beginning of period	4,435
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases	(39)
Fair value of contingent consideration liability, end of period	4,470
Contingent Consideration Liability, Noncurrent, Fair Value Disclosure	3,573	4,228
Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent Consideration Liability, Current, Fair Value Disclosure	0	0
Fair value of contingent consideration liability, beginning of period	0
Fair value of contingent consideration liability, end of period	0
Contingent Consideration Liability, Noncurrent, Fair Value Disclosure	0	$ 0
Selling, General and Administrative Expenses [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	$ 74

EQUITY AND STOCK-BASED COMPEN41

EQUITY AND STOCK-BASED COMPENSATION Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Jan. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	350,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 2,500
Proceeds from issuance of common stock, net of offering costs- ATM transactions		$ 8,514	$ 0
ATM offering [Member]
Stock Issued During Period, Shares, New Issues		882,332
Shares Issued, Price Per Share		$ 10
Proceeds from issuance of common stock, net of offering costs- ATM transactions		$ 8,500
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs		300
Maximum [Member] | ATM offering [Member]
CommonStockSharesToBeIssuedValue		$ 25,000

EQUITY AND STOCK-BASED COMPEN42

EQUITY AND STOCK-BASED COMPENSATION Equity Award Plans (Details) - shares	Mar. 22, 2018	Feb. 01, 2018	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			3,509,500
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	2,376,000	350,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			319,003
2016 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			1,000,000

EQUITY AND STOCK-BASED COMPEN43

EQUITY AND STOCK-BASED COMPENSATION Restricted Stock Awards and Restricted Stock Units Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Restricted Stock Awards and Performance Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate	15.00%	12.00%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 5.2
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 11 months
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	0	3,982
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	465,381	730,802
Contingent RSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	341,808
2016 Bonus RSU [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	131,523

EQUITY AND STOCK-BASED COMPEN44

EQUITY AND STOCK-BASED COMPENSATION Stock Options Weighted-Average Assumptions (Details) - Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	35.70%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years 1 month

EQUITY AND STOCK-BASED COMPEN45

EQUITY AND STOCK-BASED COMPENSATION Stock Options Activity (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0	21,500
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 0.7
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	11 months

EQUITY AND STOCK-BASED COMPEN46

EQUITY AND STOCK-BASED COMPENSATION Employee Stock Purchase Plan Weighted- Average Assumptions (Details) - Employee Stock Purchase Plan [Member]	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.80%	1.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	27.70%	28.50%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	1 year 4 months	1 year 4 months

EQUITY AND STOCK-BASED COMPEN47

EQUITY AND STOCK-BASED COMPENSATION Employee Stock Purchase Plan Narrative (Details)	3 Months Ended
	Mar. 31, 2018USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,509,500
Employee Stock Purchase Plan [Member] | Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Stock Purchase Plan, Maximum Contributions Per Employee, Percent	15.00%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee	2,500
Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee | $	$ 25,000
Employee Stock Purchase Plan, Stock Purchase Price, Percentage of Market Price	85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	400,000
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost | $	$ 100,000

LEASES Operating lease annual p

LEASES Operating lease annual payment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating Leased Assets [Line Items]
2,018	$ 1,549
2,019	2,132
2,020	2,181
2,021	2,223
2,022	2,243
Thereafter	6,242
Total minimum lease payments	16,570
Operating Leases, Rent Expense	$ 500	$ 700

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 73	$ 0
Reported tax rate (as a percent)	(1.00%)	0.00%

SEGMENT AND GEOGRAPHIC INFORM50

SEGMENT AND GEOGRAPHIC INFORMATION Narrative (Detail)	3 Months Ended
	Mar. 31, 2018product
Segment Reporting [Abstract]
Number of product categories	2

SEGMENT AND GEOGRAPHIC INFORM51

SEGMENT AND GEOGRAPHIC INFORMATION Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Segment Reporting Information [Line Items]
Revenues	$ 33,175	$ 31,894
United States
Segment Reporting Information [Line Items]
Revenues	29,538	28,611
International
Segment Reporting Information [Line Items]
Revenues	3,637	3,283
Orthobiologics
Segment Reporting Information [Line Items]
Revenues	18,016	17,125
Spinal implants
Segment Reporting Information [Line Items]
Revenues	$ 15,159	$ 14,769